The system was the first to allow people with diabetes to monitor blood glucose without fingersticks. Abbott’s 14-day Freestyle Libre continuous glucose monitor (CGM) has been approved by the FDA, ...

The new Flash Glucose Monitoring System enables patients to wear the sensor for up to 14 days compared with the existing FreeStyle Libre System that was approved for 10-day wear. Abbott announced that ...

ABBOTT PARK, Ill., April 8, 2020 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the FreeStyle Libre 14 day system, the world's leading 3 continuous glucose monitoring (CGM) technology, can ...

SAN FRANCISCO--(BUSINESS WIRE)--Ambrosia announced the availability of the new NightRider and LinkBluCon app. The system can be setup to notify the user if their glucose is outside their target range, ...

The FreeStyle Libre 3 system is the most accurate 14-day continuous glucose monitor1, with readings sent directly to a smartphone every minute.2 Designed for access and affordability, the FreeStyle ...

The Freestyle Libre 14 day is now the longest-lasting self-applied continuous glucose sensing technology available and allows the used to wear the sensor for up to 14 days with high accuracy. ABBOTT ...

ABBOTT PARK, Ill., Sept. 28, 2020 /PRNewswire/ -- Abbott (NYSE: ABT), the worldwide leader in continuous glucose monitoring (CGM) technology, 8 announced today it has secured CE Mark (Conformité ...

A new study published in US Endocrinology found Abbott’s continuous glucose monitoring system, the FreeStyle Libre, demonstrated significant cost savings for diabetic care compared to traditional ...

Abbott announced the US Food and Drug Administration (FDA) cleared its next-generation FreeStyle Libre 3 system for use by people four years and older living with diabetes. "The FreeStyle Libre 3 ...

(RTTNews) - Abbott (ABT) said late-breaking clinical data showed the FreeStyle Libre 3 system has an overall mean absolute relative difference (MARD) of 7.9%, making it the first and only 14-day ...

Cost model data published in U.S. Endocrinology show for commercially-insured people with diabetes on intensive insulin therapy, using FreeStyle Libre technology costs 60% less compared to traditional ...